
Marrow Therapeutics has launched with $173 million in funding to advance a preclinical therapy targeting sickle cell disease and beta thalassemia. fiercebiotech.com/biotech/ma…

The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.

Marrow Therapeutics has launched with $173 million in funding to advance a preclinical therapy targeting sickle cell disease and beta thalassemia. fiercebiotech.com/biotech/ma…

Isomorphic Labs has pulled off another massive financing, raising $5 billion in a series C just six months after securing $2.1 billion for its AI drug development platform. fiercebiotech.com/biotech/is…

Another setback for Kyntra Bio. The former FibroGen has scrapped its phase 2 prostate cancer ADC program after failing to meet an efficacy threshold. fiercebiotech.com/biotech/ky…

Could 2027 be Europe's year to shine? At Fierce's London Life Sciences Week event, investors weighed the region's biotech funding challenges and opportunities. fiercebiotech.com/biotech/fi…

Regeneron's baloncibart met the primary endpoint in a phase 2 trial for POTS, a disorder with no FDA-approved treatments. The company now plans to launch a potentially pivotal study in 2027. fiercebiotech.com/biotech/re…

Sanofi-backed Windward Bio has hit its $225M IPO target to advance its respiratory pipeline, even as fellow biotech Rezera delays its own public offering, citing market conditions. fiercebiotech.com/biotech/sa…

Cellectis plans to cut up to 70% of its workforce through 2027 as the biotech shifts away from allogeneic CAR-T therapies to focus on in vivo gene editing. fiercebiotech.com/biotech/ce…

MetaVia's GLP-1/glucagon drug reduced liver fat and body weight in a phase 1 trial, but questions remain about its competitive edge. The biotech is now targeting a less crowded corner of the liver disease market. fiercebiotech.com/biotech/me…

Rezera, formerly known as NodThera, is targeting $181 million in IPO proceeds to advance its lead NLRP3 inhibitor into a phase 3 trial for peripheral artery disease next year. fiercebiotech.com/biotech/re…

Evommune is joining Novartis in the race to develop VAV1-targeting molecular glue degraders, striking a deal worth up to $1.1 billion with China's Hinova Pharmaceuticals. fiercebiotech.com/biotech/ev…

Just two months after launching a phase 1 trial, Sanofi is pulling the plug on a STAT6 degrader licensed from Nurix. The decision comes amid a broader pipeline shake-up under Sanofi's new CEO. fiercebiotech.com/biotech/sa…

Ultragenyx is cutting 20% of its workforce and shelving drug development programs as it looks to halve R&D spending and reach profitability in 2027. The overhaul follows a string of clinical setbacks. fiercebiotech.com/biotech/ul…

Boehringer Ingelheim is doubling down on Chinese biotech innovation, striking a deal worth up to $7.4 billion with Sino Biopharmaceutical for six preclinical cancer programs spanning ADCs and T-cell engagers. fiercebiotech.com/biotech/bo…

After $2.2 billion in impairment charges weighed on quarterly profits, Novo Nordisk is still looking to acquisitions to fill gaps in its pipeline. fiercebiotech.com/biotech/no… $NVO

Enhertu has transformed HER2 breast cancer treatment and set a high bar for the next generation of drugs. Now, the race is on to develop something even better, but finding a worthy successor is proving to be easier said than done. fiercebiotech.com/biotech/ad…

Our annual Biotech Graveyard returns to remember the drug developers that shut their doors this year and the science that may yet live on. fiercebiotech.com/biotech/20…